FY2026 EPS Estimates for Precigen Decreased by Analyst

Precigen, Inc. (NASDAQ:PGEN) – Cantor Fitzgerald cut their FY2026 earnings per share estimates for Precigen in a report issued on Tuesday, August 19th. Cantor Fitzgerald analyst J. Kim now expects that the biotechnology company will post earnings of $0.07 per share for the year, down from their prior forecast of $0.11. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share.

Other analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $8.50 target price on shares of Precigen in a research report on Tuesday. JMP Securities lifted their target price on Precigen from $6.00 to $8.00 and gave the company a “market outperform” rating in a research report on Tuesday. JPMorgan Chase & Co. raised Precigen from an “underweight” rating to a “neutral” rating in a research report on Friday, August 15th. Citigroup reaffirmed an “outperform” rating on shares of Precigen in a research report on Tuesday. Finally, Wall Street Zen raised Precigen from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.25.

Precigen Price Performance

Shares of Precigen stock opened at $3.21 on Wednesday. The stock’s 50-day moving average is $1.78 and its 200-day moving average is $1.63. The firm has a market cap of $956.49 million, a price-to-earnings ratio of -7.64 and a beta of 1.87. Precigen has a one year low of $0.65 and a one year high of $3.49.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.03. The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.67 million. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%.

Hedge Funds Weigh In On Precigen

A number of institutional investors have recently bought and sold shares of the business. Envestnet Asset Management Inc. increased its position in Precigen by 29.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company’s stock worth $30,000 after buying an additional 5,915 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Precigen by 14.6% during the fourth quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 6,040 shares during the period. Rhumbline Advisers boosted its holdings in shares of Precigen by 3.7% during the second quarter. Rhumbline Advisers now owns 198,078 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 7,041 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Precigen by 12.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 9,043 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in shares of Precigen by 26.6% during the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 10,900 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.